Patents by Inventor Ivelin Stefanov Georgiev

Ivelin Stefanov Georgiev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SARS-COV-2 CORONAVIRUS ANTIBODIES AND USES THEREOF
    Publication number: 20240101646
    Abstract: The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.
    Type: Application
    Filed: January 21, 2022
    Publication date: March 28, 2024
    Inventors: Ivelin Stefanov GEORGIEV, Andrea R. SHIAKOLAS, Kevin J. KRAMER
  • Prefusion RSV F proteins and their use
    Patent number: 11878998
    Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: January 23, 2024
    Assignee: The United States of America, as represented by the Secretary Department of Health and Human Services
    Inventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
  • PREFUSION RSV F PROTEINS AND THEIR USE
    Publication number: 20240018193
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Application
    Filed: September 11, 2023
    Publication date: January 18, 2024
    Applicant: The United State of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • CROSS-REACTIVE CORONAVIRUS ANTIBODIES AND USES THEREOF
    Publication number: 20230348571
    Abstract: The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.
    Type: Application
    Filed: April 6, 2021
    Publication date: November 2, 2023
    Inventors: Ivelin Stefanov Georgiev, Andrea R. Shiakolas, Kevin J. Kramer, James E. Crowe, Jr., Robert Carnahan, Nianshuang Wang, Daniel Wrapp, Jason McLellan
  • METHODS FOR IDENTIFICATION OF LIGAND-BLOCKING ANTIBODIES AND FOR DETERMINING ANTIBODY POTENCY
    Publication number: 20230242966
    Abstract: The present disclosure relates to high-throughput systems and methods for the detection of ligand-blocking antibodies and for determining antibody potency.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 3, 2023
    Inventors: Marion Francis Setliff, Ivelin Stefanov Georgiev, Andrea Shiakolas, Kelsey PILEWSKI, Rohit VENKAT
  • RECOMBINANT VACCINES AND METHODS OF USE THEREOF
    Publication number: 20230145420
    Abstract: The present disclosure relates to recombinant nucleic acids and uses thereof for developing vaccines.
    Type: Application
    Filed: April 9, 2021
    Publication date: May 11, 2023
    Inventors: Matthew J. Vukovich, Nagarajan Raju, Amyn Murji, Ivelin Stefanov Georgiev
  • CROSS-REACTIVE ANTIBODIES AND USES THEREOF
    Publication number: 20230124977
    Abstract: The present disclosure relates to broadly neutralizing antibodies and uses thereof for treating a pathogen infection or a co-infection of multiple pathogens.
    Type: Application
    Filed: August 17, 2022
    Publication date: April 20, 2023
    Inventors: Ivelin Stefanov Georgiev, Kelsey A. Pilewski
  • METHODS FOR IDENTIFICATION OF LIGAND-BLOCKING ANTIBODIES AND FOR DETERMINING ANTIBODY POTENCY
    Publication number: 20220372551
    Abstract: The present disclosure relates to high-throughput systems and methods for the detection of ligand-blocking antibodies and for determining antibody potency.
    Type: Application
    Filed: July 22, 2021
    Publication date: November 24, 2022
    Inventors: Marion Francis Setliff, Ivelin Stefanov Georgiev, Andrea Shiakolas, Kelsey PILEWSKI, Rohit VENKAT
  • METHODS FOR IDENTIFICATION OF ANTIGEN BINDING SPECIFICITY OF ANTIBODIES
    Publication number: 20220315982
    Abstract: The present disclosure relates to a method for simultaneous detection of antigens and antigen specific antibodies. LIBRA-seq (Linking B Cell Receptor to Antigen specificity through sequencing) is developed to simultaneously recover both antigen specificity and paired heavy and light chain BCR sequence. LIBRA-seq is a next-generation sequencing-based readout for BCR-antigen binding interactions that utilizes oligonucleotides (oligos) conjugated to recombinant antigens.
    Type: Application
    Filed: September 4, 2020
    Publication date: October 6, 2022
    Inventors: Marion Francis SETLIFF, Ivelin Stefanov GEORGIEV, Andrea SHIAKOLAS
  • HIV/HCV CROSS-REACTIVE ANTIBODIES AND USES THEREOF
    Publication number: 20220185870
    Abstract: The present disclosure relates to antibodies and uses thereof for treating an HIV infection, an HCV infection, or an HIV/HCV co-infection.
    Type: Application
    Filed: April 3, 2020
    Publication date: June 16, 2022
    Inventors: Kelsey PILEWSKI, Ivelin Stefanov GEORGIEV
  • PREFUSION RSV F PROTEINS AND THEIR USE
    Publication number: 20220064222
    Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.
    Type: Application
    Filed: November 11, 2021
    Publication date: March 3, 2022
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
  • PREFUSION RSV F PROTEINS AND THEIR USE
    Publication number: 20220002351
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 6, 2022
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • Substitutions-modified prefusion RSV F proteins and their use
    Patent number: 11174292
    Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: November 16, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
  • SYSTEMS AND METHODS FOR SIMULTANEOUS DETECTION OF ANTIGENS AND ANTIGEN SPECIFIC ANTIBODIES
    Publication number: 20210302422
    Abstract: The present disclosure relates to a system for simultaneous detection of antigens and antigen specific antibodies, and methods of use thereof.
    Type: Application
    Filed: July 26, 2019
    Publication date: September 30, 2021
    Inventors: Marion Francis SETLIFF, Ivelin Stefanov GEORGIEV, Andrea SHIAKOLAS
  • Prefusion RSV F proteins and their use
    Patent number: 11130785
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: September 28, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • SUBSTITUTIONS-MODIFIED PREFUSION RSV F PROTEINS AND THEIR USE
    Publication number: 20190112340
    Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.
    Type: Application
    Filed: March 29, 2017
    Publication date: April 18, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human
    Inventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
  • PREFUSION RSV F PROTEINS AND THEIR USE
    Publication number: 20180319846
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Application
    Filed: July 2, 2018
    Publication date: November 8, 2018
    Applicant: The United States of America,as represented by the Secretary,Department of Helath and Human Services
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • Prefusion RSV F proteins and their use
    Patent number: 10017543
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 10, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • PREFUSION RSV F PROTEINS AND THEIR USE
    Publication number: 20160046675
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 18, 2016
    Applicant: The USA, as represented by the Secretary, Departm- ent of Health and Human Service
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • PREFUSION RSV F PROTEINS AND THEIR USE
    Publication number: 20140271699
    Abstract: Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Inventors: Peter Kwong, Barney Graham, Jason McLellan, Jeffrey Boyington, Ivelin Stefanov Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Marie Pancera, Cinque Soto, Sanjay Srivatsan, Baoshan Zhang